Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria

Clinical Microbiology and Infection

Volumn 23, Issue 3, 2017, Pages 167-172

  Andre, E ^a,b,c   Goeminne, L ^a   Cabibbe, A ^d   Beckert, P ^e,f   Kabamba Mukadi, B ^a,b   Mathys, V ^g   Gagneux, S ^h,i   Niemann, S ^f,j   Van Ingen, J ^b,k   Cambau, E ^c,k,l  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c European Society for Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycobacterial Infections (ESGMYC)   (Switzerland)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e RESEARCH CENTER BORSTEL   (Germany)

^f German Center for Infection Research   (Germany)

^g SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^h SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

ⁱ UNIVERSITY OF BASEL   (Switzerland)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^k HÔPITAL LARIBOISIÈRE   (France)

^l UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

Mycobacterium kansasii; Mycobacterium leprae; Mycobacterium tuberculosis; Numbering system; Resistance; Rifampicin; Rifampin; rpoB

Indexed keywords

RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; BACTERIAL PROTEIN; DNA DIRECTED RNA POLYMERASE; ESCHERICHIA COLI PROTEIN; MUTANT PROTEIN; RPOB PROTEIN, E COLI; RPOB PROTEIN, MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSTATIC AGENT;

ASSAY; BACTERIAL GENOME; BACTERIAL STRAIN; CONSENSUS NUMBERING SYSTEM; CONSENSUS SEQUENCE; ESCHERICHIA COLI; GENE MUTATION; GENE SEQUENCE; HUMAN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TUBERCULOSIS; WHOLE GENOME SEQUENCING; CONSENSUS; DRUG EFFECTS; GENETICS; GENOTYPE; GENOTYPING TECHNIQUE; MICROBIAL SENSITIVITY TEST; MUTATION; MYCOBACTERIUM; NOMENCLATURE; STANDARDS;

ANTIBIOTICS, ANTITUBERCULAR; BACTERIAL PROTEINS; CONSENSUS; DNA-DIRECTED RNA POLYMERASES; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTANT PROTEINS; MUTATION; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TERMINOLOGY AS TOPIC;

EID: 85007107209     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2016.09.006     Document Type: Short Survey

References (66)

1. [1] WHO, Global Tuberculosis Report., 2015, WHO, Geneva.
2. [2] Villarino, M.E., Geiter, L.J., Simone, P.M., The multidrug-resistant tuberculosis challenge to public health efforts to control tuberculosis. Public Health Rep 107 (1992), 616–625.
3. [3] Park, M.M., Davis, A.L., Schluger, N.W., Cohen, H., Rom, W.N., Outcome of MDR-TB patients, 1983–1993. Prolonged survival with appropriate therapy. Am J Respir Crit Care Med 153 (1996), 317–324.
4. [4] Vilcheze, C., Jacobs, W.R. Jr., Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities. Microbiol Spectr, 2, 2014 MGM2-0014–2013.
5. [5] Telenti, A., Imboden, P., Marchesi, F., Lowrie, D., Cole, S., Colston, M.J., et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341 (1993), 647–650.
6. [6] Boehme, C.C., Nabeta, P., Hillemann, D., Nicol, M.P., Shenai, S., Krapp, F., et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363 (2010), 1005–1015.
7. [7] Hillemann, D., Weizenegger, M., Kubica, T., Richter, E., Niemann, S., Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin Microbiol 43 (2005), 3699–3703.
8. [8] Rossau, R., Traore, H., De Beenhouwer, H., Mijs, W., Jannes, G., De Rijk, P., et al. Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin. Antimicrob Agents Chemother 41 (1997), 2093–2098.
9. [9] Caws, M., Duy, P.M., Tho, D.Q., Lan, N.T., Hoa, D.V., Farrar, J., Mutations prevalent among rifampin- and isoniazid-resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam. J Clin Microbiol 44 (2006), 2333–2337.
10. [10] WHO (ed), Molecular Line Probe Assays for rapid screening of patients at risk of multi-drug resistant tuberculosis (MDR-TB). 2008, WHO, Geneva.
11. [11] Mboowa, G., Namaganda, C., Ssengooba, W., Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert® MTB/RIF in Kampala, Uganda: a retrospective study. BMC Infect Dis, 14, 2014, 481.
12. [12] Williams, D.L., Waguespack, C., Eisenach, K., Crawford, J.T., Portaels, F., Salfinger, M., et al. Characterization of rifampin-resistance in pathogenic mycobacteria. Antimicrob Agents Chemother 38 (1994), 2380–2386.
13. [13] Sechi, L.A., Zanetti, S., Sanguinetti, M., Molicotti, P., Romano, L., Leori, G., et al. Molecular basis of rifampin and isoniazid resistance in Mycobacterium bovis strains isolated in Sardinia, Italy. Antimicrob Agents Chemother 45 (2001), 1645–1648.
14. [14] Diniz, L.M., Guimaraes, T., Oliveira, M., Pinto, J.A., Miranda, S.S., Lymphadenitis caused by infection with an isoniazid- and rifampin-resistant strain of Mycobacterium bovis BCG in an infant with IFN-gamma/IL-12 pathway defect. J Bras Pneumol 40 (2014), 188–192.
15. [15] Hong, D.N., Huyen, M.N., Lan, N.T., Duong, N.H., Ngo, V.V., Ngoc, D.T., et al. Rifampin-resistant Mycobacterium bovis BCG-induced disease in HIV-infected infant, Vietnam. Emerg Infect Dis 19 (2013), 1168–1170.
16. [16] Wolfe, J.N., Blackwood-Antonation, K.S., Sharma, M.K., Cook, V.J., A case of acquired rifampin resistance in Mycobacterium bovis bacillus Calmette–Guérin-induced cystitis: necessity for treatment guidelines. Can J Infect Dis Med Microbiol 17 (2006), 183–185.
17. [17] Jacobson, R.R., Hastings, R.C., Rifampin-resistant leprosy. Lancet 2 (1976), 1304–1305.
18. [18] Zhang, L., Namisato, M., Matsuoka, M., A mutation at codon 516 in the rpoB gene of Mycobacterium leprae confers resistance to rifampin. Int J Lepr Other Mycobact Dis 72 (2004), 468–472.
19. [19] Klein, J.L., Brown, T.J., French, G.L., Rifampin resistance in Mycobacterium kansasii is associated with rpoB mutations. Antimicrob Agents Chemother 45 (2001), 3056–3058.
20. [20] Reibel, F., Cambau, E., Aubry, A., Update on the epidemiology, diagnosis, and treatment of leprosy. Med Mal Infect 45 (2015), 383–393.
21. [21] Griffith, D.E., Aksamit, T., Brown-Elliott, B.A., Catanzaro, A., Daley, C., Gordin, F., et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175 (2007), 367–416.
22. [22] Ovchinnikov Yu, A., Monastyrskaya, G.S., Gubanov, V.V., Lipkin, V.M., Sverdlov, E.D., Kiver, I.F., et al. Primary structure of Escherichia coli RNA polymerase nucleotide substitution in the beta subunit gene of the rifampicin resistant rpoB255 mutant. Mol Gen Genet 184 (1981), 536–538.
23. [23] Jin, D.J., Gross, C.A., Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J Mol Biol 202 (1988), 45–58.
24. [24] Goldstein, B.P., Resistance to rifampicin: a review. J Antibiot (Tokyo) 67 (2014), 625–630.
25. [25] Cambau, E., Viveiros, M., Machado, D., Raskine, L., Ritter, C., Tortoli, E., et al. Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study. J Antimicrob Chemother 70 (2015), 686–696.
26. [26] Williamson, D.A., Roberts, S.A., Bower, J.E., Vaughan, R., Newton, S., Lowe, O., et al. Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 16 (2012), 216–220.
27. [27] Andres, S., Hillemann, D., Rusch-Gerdes, S., Richter, E., Occurrence of rpoB mutations in isoniazid-resistant but rifampin-susceptible Mycobacterium tuberculosis isolates from Germany. Antimicrob Agents Chemother 58 (2014), 590–592.
28. [28] Rigouts, L., Nolasco, O., de Rijk, P., Nduwamahoro, E., Van Deun, A., Ramsay, A., et al. Newly developed primers for comprehensive amplification of the rpoB gene and detection of rifampin resistance in Mycobacterium tuberculosis. J Clin Microbiol 45 (2007), 252–254.
29. [29] Sanchez-Padilla, E., Merker, M., Beckert, P., Jochims, F., Dlamini, T., Kahn, P., et al. Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland. N Engl J Med 372 (2015), 1181–1182.
30. [30] Heep, M., Rieger, U., Beck, D., Lehn, N., Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob Agents Chemother 44 (2000), 1075–1077.
31. [31] Miller, L.P., Crawford, J.T., Shinnick, T.M., The rpoB gene of Mycobacterium tuberculosis. Antimicrob Agents Chemother 38 (1994), 805–811.
32. [32] Van Deun, A., Aung, K.J., Hossain, A., de Rijk, P., Gumusboga, M., Rigouts, L., et al. Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients. Int J Tuberc Lung Dis 19 (2015), 185–190.
33. [33] Sandgren, A., Strong, M., Muthukrishnan, P., Weiner, B.K., Church, G.M., Murray, M.B., Tuberculosis drug resistance mutation database. PLoS Med, 6, 2009, e2.
34. [34] Maeda, S., Matsuoka, M., Nakata, N., Kai, M., Maeda, Y., Hashimoto, K., et al. Multidrug resistant Mycobacterium leprae from patients with leprosy. Antimicrob Agents Chemother 45 (2001), 3635–3639.
35. [35] Cambau, E., Bonnafous, P., Perani, E., Sougakoff, W., Ji, B., Jarlier, V., Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. Clin Infect Dis 34 (2002), 39–45.
36. [36] Yoshida, S., Suzuki, K., Tsuyuguchi, K., Iwamoto, T., Tomita, M., Okada, M., et al. [Detection of rpoB mutations in rifampicin-resistant Mycobacterium kansasii]. Kekkaku 81 (2006), 475–479.
37. [37] Cambau, E., Chauffour-Nevejans, A., Tejmar-Kolar, L., Matsuoka, M., Jarlier, V., Detection of antibiotic resistance in leprosy using GenoType LepraeDR, a novel ready-to-use molecular test. PLoS Negl Trop Dis, 6, 2012, e1739.
38. [38] Phelan, J., Coll, F., McNerney, R., Ascher, D.B., Pires, D.E., Furnham, N., et al. Mycobacterium tuberculosis whole genome sequencing and protein structure modelling provides insights into anti-tuberculosis drug resistance. BMC Med, 14, 2016, 31.
39. [39] Farhat, M.R., Sultana, R., Iartchouk, O., Bozeman, S., Galagan, J., Sisk, P., et al. Genetic determinants of drug resistance in Mycobacterium tuberculosis and their diagnostic value. Am J Respir Crit Care Med 194 (2016), 621–630.
40. [40] Honore, N., Cole, S.T., Molecular basis of rifampin resistance in Mycobacterium leprae. Antimicrob Agents Chemother 37 (1993), 414–418.
41. [41] Sapkota, B.R., Ranjit, C., Neupane, K.D., Macdonald, M., Development and evaluation of a novel multiple-primer PCR amplification refractory mutation system for the rapid detection of mutations conferring rifampicin resistance in codon 425 of the rpoB gene of Mycobacterium leprae. J Med Microbiol 57 (2008), 179–184.
42. [42] WHO (ed), Guidelines for Global Surveillance of Drug Resistance in Leprosy. 2009, WHO, Geneva.
43. [43] Cole, S., Eiglmeier, K., Parkhill, J., James, K., Thomson, N., Wheeler, P., et al. Massive gene decay in the leprosy bacillus. Nature 409 (2001), 1007–1011.
44. [44] Li, W., Matsuoka, M., Kai, M., Thapa, P., Khadge, S., Hagge, D.A., et al. Real-time PCR and high-resolution melt analysis for rapid detection of Mycobacterium leprae drug resistance mutations and strain types. J Clin Microbiol 50 (2012), 742–753.
45. [45] Lonnroth, K., Raviglione, M., The WHO's new End TB Strategy in the post-2015 era of the Sustainable Development Goals. Trans R Soc Trop Med Hyg 110 (2016), 148–150.
46. [46] André, E.I.C., Affolabi, D., Alagna, R., Brockmann, D., de Jong, B.C., Cambau, E., et al. Connectivity of diagnostic technologies: improving surveillance and accelerating tuberculosis elimination. Int J Tuberc Lung Dis 20 (2016), 999–1003.
47. [47] Kearse, M., Moir, R., Wilson, A., Stones-Havas, S., Cheung, M., Sturrock, S., et al. Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics 28 (2012), 1647–1649.
48. [48] El-Hajj, H.H., Marras, S.A., Tyagi, S., Kramer, F.R., Alland, D., Detection of rifampin resistance in Mycobacterium tuberculosis in a single tube with molecular beacons. J Clin Microbiol 39 (2001), 4131–4137.
49. [49] Lawn, S.D., Nicol, M.P., Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol 6 (2011), 1067–1082.
50. [50] Hillemann, D., Rusch-Gerdes, S., Richter, E., Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 45 (2007), 2635–2640.
51. [51] Williamson, D.A., Basu, I., Bower, J., Freeman, J.T., Henderson, G., Roberts, S.A., An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis. Diagn Microbiol Infect Dis 74 (2012), 207–209.
52. [52] Alonso, M., Palacios, J.J., Herranz, M., Penedo, A., Menendez, A., Bouza, E., Garcia de Viedma D. Isolation of Mycobacterium tuberculosis strains with a silent mutation in rpoB leading to potential misassignment of resistance category. J Clin Microbiol 49 (2011), 2688–2690.
53. [53] Mathys, V., van de Vyvere, M., de Droogh, E., Soetaert, K., Groenen, G., False-positive rifampicin resistance on Xpert® MTB/RIF caused by a silent mutation in the rpoB gene. Int J Tuberc Lung Dis 18 (2014), 1255–1257.
54. [54] Ocheretina, O., Byrt, E., Mabou, M.M., Royal-Mardi, G., Merveille, Y.M., Rouzier, V., et al. False-positive rifampin resistant results with Xpert MTB/RIF version 4 assay in clinical samples with a low bacterial load. Diagn Microbiol Infect Dis 85 (2016), 53–55.
55. [55] Pai, M., Schito, M., Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects. J Infect Dis 211:Suppl 2 (2015), S21–S28.
56. [56] Kohl, T.A., Diel, R., Harmsen, D., Rothganger, J., Walter, K.M., Merker, M., et al. Whole-genome-based Mycobacterium tuberculosis surveillance: a standardized, portable, and expandable approach. J Clin Microbiol 52 (2014), 2479–2486.
57. [57] Walker, T.M., Kohl, T.A., Omar, S.V., Hedge, J., Del Ojo Elias, C., Bradley, P., et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis 15 (2015), 1193–1202.
58. [58] Yuen, L.K., Leslie, D., Coloe, P.J., Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia. J Clin Microbiol 37 (1999), 3844–3850.
59. [59] Siu, G.K., Zhang, Y., Lau, T.C., Lau, R.W., Ho, P.L., Yew, W.W., et al. Mutations outside the rifampicin resistance-determining region associated with rifampicin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 66 (2011), 730–733.
60. [60] Bobadilla-del-Valle, M., Ponce-de-Leon, A., Arenas-Huertero, C., Vargas-Alarcon, G., Kato-Maeda, M., Small, P.M., et al. rpoB Gene mutations in rifampin-resistant Mycobacterium tuberculosis identified by polymerase chain reaction single-stranded conformational polymorphism. Emerg Infect Dis 7 (2001), 1010–1013.
61. [61] Heep, M., Brandstatter, B., Rieger, U., Lehn, N., Richter, E., Rusch-Gerdes, S., et al. Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J Clin Microbiol 39 (2001), 107–110.
62. [62] McCammon, M.T., Gillette, J.S., Thomas, D.P., Ramaswamy, S.V., Graviss, E.A., Kreiswirth, B.N., et al. Detection of rpoB mutations associated with rifampin resistance in Mycobacterium tuberculosis using denaturing gradient gel electrophoresis. Antimicrob Agents Chemother 49 (2005), 2200–2209.
63. [63] Rigouts, L., Gumusboga, M., de Rijk, W.B., Nduwamahoro, E., Uwizeye, C., de Jong, B., et al. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol 51 (2013), 2641–2645.
64. [64] Coll, F., McNerney, R., Preston, M.D., Guerra-Assuncao, J.A., Warry, A., Hill-Cawthorne, G., et al. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. Genome Med, 7, 2015, 51.
65. [65] Cole, S.T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393 (1998), 537–544.
66. [66] Maruri, F., Sterling, T.R., Kaiga, A.W., Blackman, A., van der Heijden, Y.F., Mayer, C., et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 67 (2012), 819–831.